{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03222453",
      "OrgStudyIdInfo": {
        "OrgStudyId": "201508020258"
      },
      "Organization": {
        "OrgFullName": "The Third Affiliated Hospital of Guangzhou Medical University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Thalassemia Treatment Based on the Stem Cell Technology",
      "OfficialTitle": "The Third Affiliated Hospital of Guangzhou Medical University"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2017",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 1, 2015",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 14, 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2017",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 23, 2017",
      "StudyFirstSubmitQCDate": "July 17, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 19, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 17, 2017",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 19, 2017",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Xiaofang Sun",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "The Third Affiliated Hospital of Guangzhou Medical University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Xiaofang Sun",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Nanfang Hospital of Southern Medical University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Third Affiliated Hospital, Sun Yat-Sen University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "In order to study the transplantation effect of hematopoetic stem cells from beta-thalassemia induced pluripotent stem cells. We applied clinical grade source of autologous hematopoietic stem cell for the treatment of beta-thalassemia patients, detecting the homing of hematopoietic stem cell transplantation, the differentiation of hematopoietic stem cells in vivo and the hemoglobin beta-chain (HBB) protein expression in the body of recovery, etc., as well as to make a research on the efficacy and safety of hematopoietic stem cells from beta-thalassemia induced pluripotent stem cells.",
      "DetailedDescription": "On a Good Manufacturing Practice(GMP) condition, we establish non-exotic of different mutation types of beta-thalassemia -induced pluripotent stem cells（iPS） and make a comparisons of the stability and the differentiation of efficiency of these iPS cells inducing from different sources with foreign gene integration.\nUsing the technique of artificial nuclease and in situ repairmen, we establish efficient system for different beta-thalassemia mutation site and in view of the security of these system.\nEstablish a repaired beta-thalasemia gene mutated differentiation of iPS technology system.\nBuild a functional gene therapy self-limiting slow viruses, optimizing the preparation system and to establish a virus preparation of infection of hematopoietic stem cell technology system under the GMP condition.\nEstablish humanized beta-mice model, evaluate the safety of the iPS cell of gene therapy and efficiency before the clinical experiment.\nImprove the existing hematopoietic stem cell transplant(HSCT) clinical application solutions, detect rate of graft rejection, rate of transplantation and other indicators, finish the evaluation of application by clinical cases."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Beta-Thalassemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "thalassemia",
          "stem cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "2",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Intervention Patient",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Hematopoetic stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "non-intervention Patient",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "No treatment"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Hematopoetic stem cells",
            "InterventionDescription": "Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Intervention Patient"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The check of granulocyte transplantation-granulocyte plant living standards",
            "PrimaryOutcomeDescription": "Granulocyte plant living standards for three days in a row after transplantation granulocyte should be greater than 0.5 x 109 / L,",
            "PrimaryOutcomeTimeFrame": "3 days"
          },
          {
            "PrimaryOutcomeMeasure": "The check of granulocyte transplantation-platelet plant living standards",
            "PrimaryOutcomeDescription": "Platelet plant living standard for seven consecutive days after transplantation the platelet should be greater than 20 x 109 / L and infusion.",
            "PrimaryOutcomeTimeFrame": "seven consecutive days"
          },
          {
            "PrimaryOutcomeMeasure": "Effect of cell transplantation",
            "PrimaryOutcomeDescription": "The granulocyte plant living standards and platelet plant living standards will be combined to measure the effect of cell transplantation.",
            "PrimaryOutcomeTimeFrame": "seven days"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nThe genetic diagnosis confirmed homozygous for beta to poverty or double heterozygote, clinical severe anemia;\nAged 1 ~ 18 years old, no obvious iron overload cause organ damage;\nHas a suitable donor HLA high resolution;\nThe informed consent\n\nExclusion Criteria:\n\nThere has been a significant increase in the level of tumor markers (AFP/CEA/CA199 / CA125) in the past five years.\nSerious primary diseases such as cardiovascular, liver and hematopoietic systems; Those who have major organs with serious function; An adrenal disease or other disease that causes the organ failure of the organ;\nAn autoimmune disease, a family history of genetic disease, and an abnormal thyroid function;\nPeripheral blood chromosome checking for nuclear aliens;\nHIV, hepatitis b or hepatitis c;\nA person with a history of severe drug allergies or an allergic person;\nThose who do not expect to live for more than one year;\nThe researchers suggest that the patient may have a potential or have a disorder (such as an uncontrolled infection, right heart failure, pulmonary hypertension) that is interfering with this study.\nIn the first six months, alcohol and other substance abuse were not allowed;\nSubjects who participated in other clinical trials or participated in other clinical trials within 3 months.",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "Male",
      "GenderBased": "Yes",
      "GenderDescription": "Clinical diagnosis.",
      "MinimumAge": "1 Year",
      "MaximumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "AnnotationSection": {
    "AnnotationModule": {
      "UnpostedAnnotation": {
        "UnpostedResponsibleParty": "Xiaofang Sun, Principal Investigator, The Third Affiliated Hospital of Guangzhou Medical University",
        "UnpostedEventList": {
          "UnpostedEvent": [
            {
              "UnpostedEventType": "Release",
              "UnpostedEventDate": "May 3, 2018"
            },
            {
              "UnpostedEventType": "Reset",
              "UnpostedEventDate": "November 30, 2018"
            },
            {
              "UnpostedEventType": "Release",
              "UnpostedEventDate": "September 23, 2019"
            },
            {
              "UnpostedEventType": "Reset",
              "UnpostedEventDate": "October 16, 2019"
            }
          ]
        }
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000013789",
            "ConditionMeshTerm": "Thalassemia"
          },
          {
            "ConditionMeshId": "D000017086",
            "ConditionMeshTerm": "beta-Thalassemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000000745",
            "ConditionAncestorTerm": "Anemia, Hemolytic, Congenital"
          },
          {
            "ConditionAncestorId": "D000000743",
            "ConditionAncestorTerm": "Anemia, Hemolytic"
          },
          {
            "ConditionAncestorId": "D000000740",
            "ConditionAncestorTerm": "Anemia"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000006453",
            "ConditionAncestorTerm": "Hemoglobinopathies"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15709",
            "ConditionBrowseLeafName": "Thalassemia",
            "ConditionBrowseLeafAsFound": "Thalassemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18560",
            "ConditionBrowseLeafName": "beta-Thalassemia",
            "ConditionBrowseLeafAsFound": "Beta Thalassemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3222",
            "ConditionBrowseLeafName": "Anemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3225",
            "ConditionBrowseLeafName": "Anemia, Hemolytic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8699",
            "ConditionBrowseLeafName": "Hemolysis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3227",
            "ConditionBrowseLeafName": "Anemia, Hemolytic, Congenital",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8691",
            "ConditionBrowseLeafName": "Hemoglobinopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5622",
            "ConditionBrowseLeafName": "Thalassemia",
            "ConditionBrowseLeafAsFound": "Thalassemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T737",
            "ConditionBrowseLeafName": "Beta-thalassemia",
            "ConditionBrowseLeafAsFound": "Beta Thalassemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}